Elliott Publishes Letter on GlaxoSmithKline
Elliott believes GSK has a substantial value creation opportunity 45% upside in its share price ahead of Consumer Health separation and greater beyond
Despite its strengths, GSK has a poor record of operational execution and value creation, leading to scepticism…
